Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR 深 滬
等待開盤 03-26 09:30:00 美东时间
30.28
+0.335
+1.12%
華盛通- 最 高31.65
- 今 開30.47
- 成交量 36.85万股
- 最 低 30.28
- 昨 收 29.945
- 總市值 15.35亿
- 52周最高 40.7147
- 市盈率 靜 --
- 換手率 0.73%
- 52周最低 23.15
- 委 比 -82.80%
- 總股本 5069.51万
- 歷史最高 76.98
- 量 比 1.01
- 振 幅 4.58%
- 歷史最低 18.43
- 每 手 1
- 風險率 2.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore will present five-year overall survival data from the Phase 3 trial of KIMMTRAK for metastatic uveal melanoma at the 2026 AACR meeting. The presentation will include additional data on subsequent treatments and prognostic factors. KIMMTRAK is the firstImmTAC molecule approved for treating HLA-A*02:01-positive patients with this rare and aggressive cancer. The product carries important safety warnings for cytokine release syndrome, skin...
03-17 20:30
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Jefferies Downgrades Immunocore Holdings to Hold, Lowers Price Target to $33
Jefferies analyst Clara Dong downgrades Immunocore Holdings (NASDAQ:IMCR) from Buy to Hold and lowers the price target from $48 to $33.
03-16 20:53
Immunocore to present at upcoming investor conferences
Immunocore Holdings plc (Nasdaq: IMCR), a biotech company developing transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, announced that its management will participate in several investor conferences in March 2026. These include the TD Cowen Annual Healthcare Conference on March 3, the Leerink Global Healthcare Conference on March 9, and multiple sessions at the Barclay Global Healthcare Conference,...
03-03 12:00
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
Needham Maintains Buy on Immunocore Holdings, Raises Price Target to $75
Needham analyst Gil Blum maintains Immunocore Holdings (NASDAQ:IMCR) with a Buy and raises the price target from $71 to $75.
02-26 19:34
Immunocore Holdings Q4 Earnings Report: What Investors Need to Know
Immunocore Holdings (NASDAQ:IMCR) announced its Q4 earnings on Wednesday, Febru...
02-25 20:10
Immunocore misses Q4 earnings
Immunocore press release (IMCR): Q4 GAAP EPS of -$0.60 misses by $0.42. Revenue of $104.48M (+24.3% Y/Y) misses by $3.29M. Cash, cash equivalents and marketable securities of $864.2 million as of Dece...
02-25 20:10
Immunocore Hldgs Q4 EPS $(0.60) Misses $(0.23) Estimate, Sales $104.478M Miss $107.310M Estimate
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.23) by 164.32 percent. This is a 27.66 percent decrease over losses of $(0.47) per share
02-25 20:08
Earnings Scheduled For February 25, 2026
Companies Reporting Before The Bell • Clear Secure (NYSE:YOU) is expected to re...
02-25 19:11
